GERN Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Geron Will Benefit from European Approval of RYTELO in Myelodysplastic Syndromes
Geron Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.65 |
| 52 Week High | US$5.34 |
| 52 Week Low | US$1.46 |
| Beta | 0.53 |
| 1 Month Change | -6.25% |
| 3 Month Change | -53.39% |
| 1 Year Change | -47.95% |
| 3 Year Change | 1.85% |
| 5 Year Change | 47.32% |
| Change since IPO | -78.71% |
Recent News & Updates
Geron Corp: How Concerned Should We Be About Rytelo Sales?
Mar 17Risks Still Elevated At These Prices As Geron Corporation (NASDAQ:GERN) Shares Dive 45%
Mar 12
Recent updates
Geron Corp: How Concerned Should We Be About Rytelo Sales?
Mar 17Risks Still Elevated At These Prices As Geron Corporation (NASDAQ:GERN) Shares Dive 45%
Mar 12We're Hopeful That Geron (NASDAQ:GERN) Will Use Its Cash Wisely
Feb 27Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales
Feb 26Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch
Feb 03Geron: A Post Earnings And Funding Announcement Assessment
Nov 07Is Geron (NASDAQ:GERN) Using Too Much Debt?
Oct 28Geron's Rytelo Gains Traction Despite Competitive Pressures (Rating Upgrade)
Aug 12Geron: Probabilistic And Modest Estimate Of Pricing For A Likely Acquisition
Jul 31Does Geron (NASDAQ:GERN) Have A Healthy Balance Sheet?
Jul 12Geron: Innovative Rytelo Enters A Challenging MDS Market
Jun 08Why We Think Geron Corporation's (NASDAQ:GERN) CEO Compensation Is Not Excessive At All
May 03Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy
Mar 15Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA
Mar 05Is Geron (NASDAQ:GERN) A Risky Investment?
Aug 25Is Geron (NASDAQ:GERN) Using Debt Sensibly?
May 12Shareholder Returns
| GERN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.7% | -2.3% | -3.5% |
| 1Y | -47.9% | -8.9% | 5.8% |
Return vs Industry: GERN underperformed the US Biotechs industry which returned -8.9% over the past year.
Return vs Market: GERN underperformed the US Market which returned 5.8% over the past year.
Price Volatility
| GERN volatility | |
|---|---|
| GERN Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: GERN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GERN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 229 | Dawn Bir | www.geron.com |
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Fundamentals Summary
| GERN fundamental statistics | |
|---|---|
| Market cap | US$1.05b |
| Earnings (TTM) | -US$174.57m |
| Revenue (TTM) | US$76.99m |
13.6x
P/S Ratio-6.0x
P/E RatioIs GERN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GERN income statement (TTM) | |
|---|---|
| Revenue | US$76.99m |
| Cost of Revenue | US$104.99m |
| Gross Profit | -US$28.00m |
| Other Expenses | US$146.57m |
| Earnings | -US$174.57m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | -36.37% |
| Net Profit Margin | -226.73% |
| Debt/Equity Ratio | 42.3% |
How did GERN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/31 10:18 |
| End of Day Share Price | 2025/03/28 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Geron Corporation is covered by 29 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carter Gould | Barclays |
| Peter Lawson | Barclays |
| Andrew D'Silva | B. Riley Securities, Inc. |